Senti Biosciences Inc (NAS:SNTI)

$ 4.0273 -0.1427 (-3.42%) Market Cap: 19.14 Mil Enterprise Value: 43.37 Mil PE Ratio: 0 PB Ratio: 1.20 GF Score: 18/100

Senti Biosciences Inc at Chardan Genetic Medicines Conference Transcript
Oct 03, 2023
Senti Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Senti Biosciences Inc at HC Wainwright Investment Conference - New York ( Pre-recorded Presentation ) Transcript
Sep 11, 2023
Senti Biosciences Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023

Senti Biosciences Inc at Chardan Genetic Medicines Conference Transcript

Oct 03, 2023 / 05:30PM GMT

Release Date Price: $4.01 (-6.72%)

Transcript

Unidentified Participant;Moderator

Introducing our next guest, we have Dr. Tim Lu, Co-Founder and CEO; and Dr. Deb Knobelman, CFO and Head of Corporate Development of Senti Bio. The format for this session is a fireside chat and thank you both for joining us today. To begin with, let's start with a brief overview of Senti and hitting the highlights on the recent updates and upcoming catalysts.

Tim Liu

Senti Biosciences, Inc. - CoFounder and CEO

So thanks a lot for that, happy to be here. Senti, at the heart of it, is a what we call gene circuits company, which means that we essentially are designing multifunctional capabilities into cell and gene therapies broadly. So our products are really focused on how to endow cells with more precise targeting, control, as well as greater efficacy. And we do this by essentially introducing multi-gene constructs into living cells and programming those genes in a way that allows us to achieve dynamic precision functionality. We've basically been focused internally on developing a pipeline of oncology programs,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.